Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4894-4903

  Nguyen, Stephanie A ^a,b   Stechishin, Owen D M ^a,b   Luchman, H Artee ^a,b   Lun, Xueqing Q ^b   Senger, Donna L ^b   Robbins, Stephen M ^b   Cairncross, J Gregory ^a,b   Weiss, Samuel ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; DACARBAZINE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE; G-T MISMATCH-BINDING PROTEIN; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DNA METHYLATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; GENOTYPE; GLIOBLASTOMA; HUMAN; MALE; MIDDLE AGED; MOUSE; MUTATION; OLIGODENDROGLIOMA; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; BRAIN NEOPLASMS; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; GLIOBLASTOMA; HUMANS; MALE; MICE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84907426055     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1856     Document Type: Article

References (25)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
4. Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. J Neurooncol 2011;105:325-35.
5. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
6. York SJ, Modrich P. Mismatch repair-dependent iterative excision at irreparableO6-methylguanine lesions in human nuclear extracts. J Biol Chem 2006;281:22674-83.
7. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009;15: 4622-9.
8. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006;66:3987-91.
9. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair proteinMSH6 in human glioblastoma is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-45.
10. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008;14:4859-68.
11. Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, et al. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 2009;27:1722-33.
12. Kelly JJ, Blough MD,Stechishin O, Chan J, Beauchamp D, Perizzolo M, et al. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol 2010;12:745-55.
13. Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, et al. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. Neuro Oncol 2013;15:198-207.
14. Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 2012;14:184-91.
15. Pei C, Chen H, Jia X, Yan L, Zou Y, Jiang C, et al. A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma. Int J Neurosci 2013;123:114-20.
16. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
17. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009;27:1262-7.
18. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
19. Tang JB, Svilar D, Trivedi RN, Wang X, Goellner EM, Moore B, et al. Nmethylpurine DNA glycosylase and DNA polymerase {beta}modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol 2011;13:471-86.
20. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, et al. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 2012;122:253-66.
21. Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, et al. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res 2010;70:9243-52.
22. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995;332:839-47.
23. Ilencikova D, Sejnova D, Jindrova J, Babal P. High-grade brain tumors in siblings with biallelic MSH6 mutations. Pediatr Blood Cancer 2011;57:1067-70.
24. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011;129:659-70.
25. Stark AM, Doukas A, Hugo HH, Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 2010;32:816-20.